TABLE 1.
Characteristics of the positive COVID‐19 population according to anti‐CD‐20 type (n = 47)
| Variable | Total (n = 47) | Rituximab (n = 27) | Obinutuzumab (n = 20) | p value |
|---|---|---|---|---|
| Baseline characteristics | ||||
| Age (mean ± SD) | 65.3 ± 12.2 | 65.7 ± 14.9 | 64.8 ± 7.8 | 0.769 |
| Gender, female n (%) | 23 (48.9) | 18 (66.7) | 5 (25.0) | 0.005 |
| Charlson (median, IQR) | 6.0, 4.0–8.0 | 6, 4.0–8.0 | 6, 4.0–7.7 | 0.712 |
| Charlson ≥ 4 n (%) | 39 (83.0) | 22 (81.5) | 17 (85.0) | 1.00 |
| Hypertension n (%) | 21 (44.7) | 13 (48.1) | 8 (40.0) | 0.579 |
| Diabetes mellitus n (%) | 13 (27.7) | 5 (18.5) | 8 (40.0) | 0.104 |
| Haematological malignancy status | ||||
| Haematologic diagnosis n (%) | ||||
| Aggressive lymphoma | 16 (34.0) | 16 (59.3) | 0 (0) | <0.001 |
| Indolent lymphoma/CLL | 31 (66.0) | 11 (40.7) | 20 (100.0) | |
| s/p CAR‐T n (%) | 3 (6.4) | 3 (11.1) | 0 (0) | 0.251 |
| s/p HSCT n (%) | 3 (6.4) | 3 (11.1) | 0 (0) | 0.251 |
| Anti‐CD20 indication n (%) | ||||
| Induction | 28 (59.6) | 21 (77.8) | 7 (35.0) | 0.003 |
| Maintenance | 19 (40.4) | 6 (22.2) | 13 (65.0) | |
| Remission n (%) | 36 (76.6) | 21 (77.8) | 15 (75.0) | 0.824 |
| Relapse or refractory disease n (%) | 13 (27.7) | 8 (29.6) | 5 (27.7) | 0.726 |
| Vaccination status n (%) | ||||
| 0–2 doses | 12 (25.5) | 7 (25.9) | 5 (25.0) | 0.943 |
| 3–4 doses | 35 (74.5) | 20 (74.1) | 15 (75.0) | |
| Covid‐19 disease | ||||
| Covid severity n (%) | ||||
| Asymptomatic‐mild–moderate | 38 (80.9) | 25 (92.6) | 13 (65.0) | 0.017 |
| Severe–critical | 9 (19.1) | 2 (7.4) | 7 (35.0) | |
| Time from last anti‐CD‐20 to COVID‐19 infection, days (median, IQR) | 49.0, 16.0–171.0 | 62.0, 18.0–217.0 | 47.5, 14.5–66.0 | 0.186 |
| Hospitalisations n (%) | 19 (40.4) | 7 (25.9) | 12 (60.0) | 0.019 |
| Hospital LOS (median, IQR) (n = 19) | 5.0, 3.0–13.0 | 4.0, 2.0–8.0 | 5.5, 3.2–14.5 | 0.523 |
| Elevated CRP (≥0.5 mg/dl) n (%) (n = 21) | 21 (100) | 8 (100) | 13 (100) | 1.00 |
| Lymphopenia (<900 a 103/μl) n (%) (n = 28) | 19 (67.9) | 8 (61.5) | 11 (73.3) | 0.689 |
| Neutropenia (<1000 a 103/μl) n (%) (n = 28) | 5 (17.9) | 2 (15.4) | 3 (20.0) | 1.00 |
| Treatment n (%) | ||||
| Glucocorticoids | 10 (21.3) | 3 (11.1) | 7 (35.0) | 0.048 |
| Remdesivir | 11 (23.4) | 4 (14.8) | 7 (35.0) | 0.106 |
| Nirmatrelvir/ritonavir | 12 (25.5) | 8 (29.6) | 4 (20.0) | 0.454 |
| Molupiravir | 6 (12.8) | 4 (14.8) | 2 (10.0) | 1.00 |
| Any anti‐viral a | 25 (53.2) | 12 (44.4) | 13 (65.0) | 0.163 |
| Baricitinib | 2 (4.3) | 1 (3.7) | 1 (5.0) | 1.00 |
| Tixagevimab–cilgavimab | ||||
| Pre‐ exposure | 3 (6.4) | 1 (3.7) | 2 (10.0) | 0.549 |
| Post‐exposure | 10 (21.3) | 5 (18.5) | 5 (25.0) | |
| Outcomes | ||||
| Mortality n (%) | 3 (6.4) | 0 (0) | 3 (15.0) | 0.038 |
| ICU hospitalisation n (%) | 4 (8.5) | 1 (3.7) | 3 (15.0) | 0.298 |
| Cumulative follow‐up weeks | 753.4 | 430.4 | 323.0 | — |
Abbreviations: CAR‐T, chimaeric antigen receptor (CAR) T‐cell therapy; CLL, chronic lymphocytic leukaemia; CRP, C‐reactive protein, normal range 0.02–0.5 mg/dl; HSCT, haematopoietic stem cell transplantation; ICU, intensive‐care unit; IQR, interquartile range; LOS, length of stay; SD standard deviation.
a
Any antiviral medication—remdesivir, ritonavir‐boosted nirmatrelvir or molnupiravir.